Pharmacies are taking a more active and creative role in healthcare delivery, evolving beyond routine prescription dispensers into independent healthcare stakeholders with expanded roles and tech-driven capabilities. From prior authorizations and price transparency to adherence tools and prescriber-facing portals, these prescribing-adjacent services are reshaping the market and attracting interest from investors and strategic partners.

Join McDermott for an in-depth discussion on how investors can capitalize on this transformation while mitigating regulatory risk. This program will explore:

• Vendor arrangements and business conversions: How shifting operations in-house and strategic partnerships are changing the game, and how to do it within regulatory guardrails
• Prescribing-adjacent services: Where consumerization meets pharma services—and how investors can capitalize on efficiencies within adherence, price transparency, medication therapy management, and more
• 340B program dynamics: Why investors are entering this space and what risks and opportunities they need to understand
• Risk and compliance considerations: Key diligence points around prior authorization and operational optimization